Metabolic Disorders · Urea Cycle DisorderRegulatory Approvalregulatorymid-term

Teva's Glycerol Phenylbutyrate ANDA218738 Receives AP Status from FDA

Importance7/ 10

ActionMonitor

View Company Intelligence

Explore aggregated signals, assets, and competitive context for organizations linked to this signal.

Teva16 signalsView page

AutoResearch

Multi-agent research across ingested FDA, EMA, MHRA, PMDA, PubMed, ClinicalTrials.gov, company documents, and Humanexa signals.

Last run 7/3/2026, 12:33:38 PM

Assessment confidence: 80% · The main uncertainty is timing and magnitude of competitive and regulatory follow-through.

Executive Thesis

Teva's receipt of AP status for Glycerol Phenylbutyrate is significant as it enhances their competitive positioning in the metabolic disorder market. This approval could lead to increased market share and influence pricing strategies in a niche therapeutic area. Regulatory context from FDA (FDA AP — GLYCEROL PHENYLBUTYRATE (ORIG)) supports the near-term read. Assessment grounded in 23 ranked evidence items (17 high-relevance).

Strategic Assessment

Strategic focus on market entry strategies and potential pricing models will be crucial as Teva prepares for launch. The strongest clinical anchor is Familial Mediterranean Fever and Related Disorders: Genetics and Disease Characteristics (ClinicalTrials.gov), sponsor/company relevance (merck). In Metabolic Disorders · Urea Cycle Disorder, 8 regulatory and 6 competitive items passed relevance filtering for Teva.

Competitive Pressure

The most relevant competitive pressure comes from Roche receives CE mark for new blood test to detect Alzheimer's pathology: Elecsys® plasma phosphorylated-tau 217 (pTau217) (Roche) — sponsor/company relevance (roche). Secondary pressure from Roche receives CE mark for new blood test to detect Alzheimer's pathology: Elecsys® plasma phosphorylated-tau 217 (pTau217).

Regulatory Outlook

Regulatory risk is concentrated around FDA AP — GLYCEROL PHENYLBUTYRATE (ORIG) (FDA). Entity match (teva); Regulatory pathway relevance (nda). While the AP status is a positive step, the final approval and subsequent market launch will be critical for compliance and operational readiness.

Key Risks

Elevated medium regulatory exposure for Teva could delay market entry or constrain labeling if agency review intensifies.
Clinical risk from ClinicalTrials.gov (The Psoriasis, Atherosclerosis, and Cardiometabolic Disease Initiative (PACI)) could weigh on Teva through efficacy or safety read-through uncertainty if follow-through weakens.

Key Opportunities

Successful market entry could bolster Teva's revenue streams and challenge existing competitors in the urea cycle disorder treatment space.
Upside for Teva may improve if Bicycle Continued Access Protocol (BiCAP) for Participants Receiving Bicycle Investigational Product (ClinicalTrials.gov) delivers favorable follow-through.
Strategic focus on market entry strategies and potential pricing models will be crucial as Teva prepares for launch.

What Would Change This Assessment

This becomes more urgent if Monitor for the final approval and market launch timelines for Glycerol Phenylbutyrate.
Timeline shift beyond mid term would change urgency.
A competitor label expansion or pivotal readout in the same sub-indication would increase competitive pressure.

Supporting Evidence

FDA AP — GLYCEROL PHENYLBUTYRATE (ORIG)
FDAhigh relevance
Entity match (teva); Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — GLYCEROL PHENYLBUTYRATE (ORIG)
FDAhigh relevance
Entity match (teva); Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — GLYCEROL PHENYLBUTYRATE (ORIG)
FDAhigh relevance
Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — GLYCEROL PHENYLBUTYRATE (ORIG)
FDAhigh relevance
Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — GLYCEROL PHENYLBUTYRATE (ORIG)
FDAhigh relevance
Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — GLYCEROL PHENYLBUTYRATE (ORIG)
FDAhigh relevance
Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — GLYCEROL PHENYLBUTYRATE (ORIG)
FDAhigh relevance
Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — GLYCEROL PHENYLBUTYRATE (ORIG)
FDAhigh relevance
Regulatory pathway relevance (nda)
FDA document
View source

Familial Mediterranean Fever and Related Disorders: Genetics and Disease Characteristics
ClinicalTrials.govhigh relevance
Sponsor/company relevance (Merck)
FDA document
View source
Evaluation and Long-Term Follow-up of Patients With Inflammatory Disorders
ClinicalTrials.govhigh relevance
Moderate corpus alignment
FDA document
View source
The Psoriasis, Atherosclerosis, and Cardiometabolic Disease Initiative (PACI)
ClinicalTrials.govhigh relevance
Moderate corpus alignment
FDA document
View source
Bicycle Continued Access Protocol (BiCAP) for Participants Receiving Bicycle Investigational Product
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Neural and Metabolic Factors in Carbohydrate Reward
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source

Roche receives CE mark for new blood test to detect Alzheimer's pathology: Elecsys® plasma phosphorylated-tau 217 (pTau217)
Rochehigh relevance
Sponsor/company relevance (Roche)
FDA document
View source
Roche receives CE mark for new blood test to detect Alzheimer's pathology: Elecsys® plasma phosphorylated-tau 217 (pTau217)
Rochehigh relevance
Sponsor/company relevance (Roche)
FDA document
View source
FDA Approves Supplemental Application for AJOVY (Fremanezumab)
Humanexa Signalshigh relevance
Entity match (teva)
FDA Accepts Roche's Gazyva for Systemic Lupus Erythematosus Treatment
Humanexa Signalshigh relevance
Sponsor/company relevance (Roche)
Roche's Elecsys® pTau217 Blood Test Receives CE Mark for Alzheimer's Diagnosis
Humanexa Signalshigh relevance
Sponsor/company relevance (Roche)
FDA Approves Casgevy for Young Children with Sickle Cell Disease
Humanexa Signalsmedium relevance
Moderate corpus alignment

Absence of autoantibodies linked to cancer and autoimmune disorders 26 weeks after BNT162b2 boosting in CoronaVac- primed individuals.
PubMedhigh relevance
Moderate corpus alignment
FDA document
View source
Gut Proteobacteria glycine metabolism regulates neuroplasticity, motivation, and reinstatement of cocaine self-administration in mice.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Effect of pasteurized Akkermansia muciniphila MucT on insulin sensitivity, body composition, and GLP-1 production in subjects with metabolic syndrome: impact of low baseline gut Akkermansia levels.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Significance of GSH and H(2)S regulation for cancer: an intricate interplay between diet, microbiota, metabolic reprogramming, and immune health.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source

Regunera

Precedents · guidance

Reg

Loading regulatory precedents…

View full regulatory analysis

Competitiva

Competitors · threats

Intel

Loading competitive findings…

View full competitive analysis

Why this matters

Affected entities

Teva
metabolic disorder market
urea cycle disorder treatments

Commercial impact

medium

Successful market entry could bolster Teva's revenue streams and challenge existing competitors in the urea cycle disorder treatment space.

Regulatory impact

medium

While the AP status is a positive step, the final approval and subsequent market launch will be critical for compliance and operational readiness.

What to watch

Monitor for the final approval and market launch timelines for Glycerol Phenylbutyrate.

Recommended action

Monitor

Track for follow-up milestones; no immediate action required.